

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Scott A. MITCHELL, et al.

Serial No.: 10/776,002

Filed: 02/10/04

For: CERTAIN 8-HETEROARYL-6-PHENYL-
IMIDAZO[1,2-a]PYRAZINES AS
MODULATORS OF KINASE ACTIVITY

)
) Group Art Unit: NYA
)
)
) Examiner: NYA
)
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

DE 43 37 609 A1, one of the documents listed on attached Form PTO-1449, is not in English. As required by 37 C.F.R. §1.98(a)(3) applicants have provided below a concise explanation of the relevance of this reference, as well as an Abstract of the PCT counterpart, WO 95/12592. Applicants do not have a translation of this document, but understand it to be directed to pyrazine carboxamide derivatives, for example, those in Table 6 at the top of page 12 and Tables 9 and 9a on pages 14-15. These compounds all have a pyrazine group at the position of W in Formula I of the application and either hydrogen, alkyl, or halogen at the 6-position of the

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Scott A. Mitchell, et al.

Docket No.

CGI-0014

Serial No.

10/776,002

Filing Date

February 10, 2004

Examiner

Not Assigned

Group Art Unit

Not Assigned

Invention: Certain Heteroaryl-6-Phenyl-Imidazo[1,2-a]Pyrazines As Modulators Of Kinase Activity

I hereby certify that this Trans. of IDS (2 pgs), IDS (2 pgs), PTO-A820 (3 pgs), Cited Art (16 refs), cert. of mail,
(Identify type of correspondence) postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on

May 6, 2004

(Date)

Laura J. Nolan

(Typed or Printed Name of Person Mailing Correspondence)

Laura J. Nolan

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

imidazo[1,2-a]pyrazine core. Compounds disclosed in the application have a substituted phenyl or pyridyl at the 6-position of the imidazo[1,2-a]pyrazine core.

Respectfully submitted,

CANTOR COLBURN LLP

By: 

Leah M. Reimer
Reg. No. 39,341

Date: May 6, 2004
Customer No. 23,413
(860) 286-2929

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
CGI-0014

In Re Application Of  Scott A. Mitchell, et al.

Serial No.
10/776,002

Filing Date
02/10/2004

Examiner
NYA

Group Art Unit
NYA

Title: Certain 8-Heteroaryl-6-Phenyl-Imidazo[1,2-a]Pyrazines As Modulators Of Kinase Activity

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)


1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
CGI-0014

In Re Application:  Scott A. Mitchell, et al.

Serial No.
10/776,000

Filing Date
02/10/2004

Examiner
NYA

Group Art Unit
NYA

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **06-1130** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:


(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **May 6, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Laura J. Nolan

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**


Signature

Dated: **May 6, 2004**

Leah M. Reimer

Reg. No. 39,341

Customer No. 23,413

(860) 286-2929

CC:

<p style="text-align: center; margin: 0;">INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <div style="position: relative; width: 100px; height: 100px; margin: 10px auto;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 24px; font-weight: bold;">OIP</div> <div style="position: absolute; bottom: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 12px;">MAY 10 2004 PATENT & TRADEMARK OFFICE</div> </div>	Docket Number (Optional) <div style="text-align: center; font-weight: bold;">CGI-0014</div>	Application Number <div style="text-align: center; font-weight: bold;">10/776,002</div>
	Applicant(s) <div style="text-align: center; font-weight: bold;">Scott A. Mitchell, et al.</div>	
	Filing Date <div style="text-align: center; font-weight: bold;">02/10/2004</div>	Group Art Unit <div style="text-align: center; font-weight: bold;">NYA</div>

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,593,997	01/14/1997	Dow et al.			
	5,658,857	08/19/1997	Andree et al.			
	5,783,576	07/21/1998	Roos et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	DE 43 37 609 A1	11.5.95	Germany				✓
	WO 88/04298	16.06.88	International				
	WO 95/12594	11.05.95	International				
	WO 96/04298	15.02.96	International				
	WO 96/34866	07.11.96	International				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Jeffery, Trina K., et al., "Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension" <i>Journal of Cardiovascular Pharmacology</i> 1998, volume 32, no. 2, pages 213-219
		Hanks, Steven K., "Hanks Classification" 1994, Pages 1-4 http://pkr.sdsc.edu/html/pk_catalytic/pk_hanks_class.html

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

